Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553366 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,075
- Enrollment target
NCT05553366 is a Phase 3 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 1,075 participants.
The verdict
NCT05553366, a Phase 3 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,075 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.
Interventions
- DRUG Placebo (matched to SUZ)
- DRUG HB/APAP
- DRUG Placebo (matched to HB/APAP)
- DRUG SUZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,075 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05553366
The ClinicalTrials.gov registry entry for NCT05553366 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,075 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo (matched to SUZ) is the first listed.
NCT05553366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05553366 about?
NCT05553366 is a clinical study titled "Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy". The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.
What is the current status of trial NCT05553366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,075 participants. The study started on 2022-10-03. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT05553366?
The interventions under investigation include: Placebo (matched to SUZ) (DRUG), HB/APAP (DRUG), Placebo (matched to HB/APAP) (DRUG), SUZ (DRUG).
Who is sponsoring clinical trial NCT05553366?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.